{"id":"vancomycin-with-taper-pulse","safety":{"commonSideEffects":[{"rate":"5-25","effect":"Nephrotoxicity (acute kidney injury)"},{"rate":"1-5","effect":"Ototoxicity (hearing loss)"},{"rate":"10-30","effect":"Red man syndrome (flushing, pruritus)"},{"rate":"5-15","effect":"Phlebitis at infusion site"},{"rate":"5-10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vancomycin is a glycopeptide antibiotic that prevents cross-linking of peptidoglycan in bacterial cell walls, leading to cell lysis and death. The taper/pulse dosing strategy involves gradually reducing or intermittently administering the drug to minimize cumulative nephrotoxicity and ototoxicity while preserving antimicrobial activity, particularly useful in chronic or recurrent infections.","oneSentence":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, and a taper/pulse dosing regimen modulates exposure to reduce toxicity while maintaining efficacy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:25.699Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious gram-positive bacterial infections (e.g., methicillin-resistant Staphylococcus aureus, MRSA)"},{"name":"Clostridium difficile infection"},{"name":"Endocarditis"}]},"trialDetails":[{"nctId":"NCT02667418","phase":"PHASE4","title":"Optimal Treatment for Recurrent Clostridium Difficile","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2016-02-19","conditions":"Clostridium, Difficile, Fidaxomicin","enrollment":308},{"nctId":"NCT04317963","phase":"","title":"Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2020-02-12","conditions":"Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence","enrollment":180},{"nctId":"NCT03880539","phase":"PHASE4","title":"Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2019-06-25","conditions":"Clostridium Difficile Infection Recurrence","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vancomycin with Taper/Pulse","genericName":"Vancomycin with Taper/Pulse","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, and a taper/pulse dosing regimen modulates exposure to reduce toxicity while maintaining efficacy. Used for Serious gram-positive bacterial infections (e.g., methicillin-resistant Staphylococcus aureus, MRSA), Clostridium difficile infection, Endocarditis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}